JNJ · News · 20260914N

Nipocalimab Development Program

JOHNSON & JOHNSON · 2026-09-14 · Importance 31 · Surprise 42

An experimental depression drug developed by Contineum Therapeutics with Johnson & Johnson failed to meet the primary efficacy endpoint in the Phase 2 MOONLIGHT-1 study. The trial measured change from baseline in the Montgomery-Åsberg Depression Rating Scale at Day 5 versus placebo. The result weakens the near-term outlook for the JNJ-5120/PIPE-307 program and may affect future development investment, although the digest does not report a discontinuation or financial charge.